Author: Yang, Yong; Cheng, Han; Yan, Hui; Wang, Pengâ€Zhan; Rong, Rong; Zhang, Yingâ€Ying; Zhang, Chengâ€Bo; Du, Ruiâ€kun; Rong, Liâ€Jun
Title: A cellâ€based highâ€throughput protocol to screen entry inhibitors of highly pathogenic viruses with Traditional Chinese Medicines Cord-id: 6rs95axb Document date: 2016_10_14
ID: 6rs95axb
Snippet: Emerging viruses such as Ebola virus (EBOV), Lassa virus (LASV), and avian influenza virus H5N1 (AIV) are global health concerns. Since there is very limited options (either vaccine or specific therapy) approved for humans against these viruses, there is an urgent need to develop prophylactic and therapeutic treatments. Previously we reported a highâ€throughput screening (HTS) protocol to identify entry inhibitors for three highly pathogenic viruses (EBOV, LASV, and AIV) using a human immunodef
Document: Emerging viruses such as Ebola virus (EBOV), Lassa virus (LASV), and avian influenza virus H5N1 (AIV) are global health concerns. Since there is very limited options (either vaccine or specific therapy) approved for humans against these viruses, there is an urgent need to develop prophylactic and therapeutic treatments. Previously we reported a highâ€throughput screening (HTS) protocol to identify entry inhibitors for three highly pathogenic viruses (EBOV, LASV, and AIV) using a human immunodeficiency virus–based pseudotyping platform which allows us to perform the screening in a BSLâ€2 facility. In this report, we have adopted this screening protocol to evaluate traditional Chinese Medicines (TCMs) in an effort to discover entry inhibitors against these viruses. Here we show that extracts of the following Chinese medicinal herbs exhibit potent antiâ€Ebola viral activities: Gardenia jasminoides Ellis, Citrus aurantium L., Viola yedoensis Makino, Prunella vulgaris L., Coix lacrymaâ€jobi L. var. mayuen (Roman.) Stapf, Pinellia ternata (Thunb.) Breit., and Morus alba L. This study represents a proofâ€ofâ€principle investigation supporting the suitability of this assay for rapid screening TCMs and identifying putative entry inhibitors for these viruses. J. Med. Virol. 89:908–916, 2017. © 2016 Wiley Periodicals, Inc.
Search related documents:
Co phrase search for related documents- active component and long history: 1
- active component and low toxicity: 1
- active component and luciferase activity: 1
- active ingredient and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- active ingredient and logistic regression: 1, 2
- active ingredient and low toxicity: 1
- acute sars cov respiratory syndrome coronavirus and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute sars cov respiratory syndrome coronavirus and long history: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute sars cov respiratory syndrome coronavirus and low cytotoxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute sars cov respiratory syndrome coronavirus and low signal: 1, 2
- acute sars cov respiratory syndrome coronavirus and low toxicity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute sars cov respiratory syndrome coronavirus and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute sars cov respiratory syndrome coronavirus and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute sars cov respiratory syndrome coronavirus and luciferase signal: 1
- acute sars cov respiratory syndrome coronavirus and luminescence signal: 1
- acute sars cov respiratory syndrome coronavirus and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- acute sars cov respiratory syndrome coronavirus and lung epithelial cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date